Dabur Pharma, Ghaziabad based company for cancer research and anticancer products, on Monday said that it received the requisite shareholders approval for the change of name of the company to Fresenius Kabi Oncology.
Last year, Fresenius Kabi, subsidiary of a German pharmaceutical company had acquired 73.27 per cent stake in Dabur Pharma from its promoters and certain other shareholders, after which Fresenius Kabi made an open offer for an additional 20 per cent stake in the firm.
